ReNeuron, the biotechnology group with strong links to Scottish research, has seen its loss widen by £1m and cash reduce by £4.8m.
The Surrey-based developer of stem cell therapies has attracted investment from the likes of top fund manager Neil Woodford who has a 20 per cent stake, and is poised to move from Surrey into purpose-built laboratories in Wales early next year.
It said last year's loss was as expected at £4.13m after the previous year's £3.17m, while cash had eroded from £20.9m in March to £16.1m at September 30.
ReNeuron conducted a groundbreaking patient trial for its stroke disability therapy at Glasgow's Southern General Hospital in 2012-13, conducted by a team from Glasgow University led by Professor Keith Muir. It reported that some patients regained movement in their limbs and showed "modest" improvements in condition, despite all having had their strokes between six months and five years earlier. Its success triggered a major investment into the group by biotechnology guru Sir Chris Evans, who joined the board in August last year.
This year ReNeuron began a Phase 1 safety study at Ninewells Hospital in Dundee of its therapy for people with lower limb ischaemia, which can lead to limb amputation.
The group yesterday cited "encouraging long term Phase 1 data" from the stroke study and said Phase II clinical trials for both therapies were planned for next year.
It also plans a clinical trial next year in the US on a stem cell therapy candidate for retinitis pigmentosa, a disease of the retina which causes blindness.
ReNeuron's therapies can be administered "off-the-shelf" without the need for immune-suppressive drug treatments.
It is also advancing a technology to exploit exosomes secreted by stem cells, as potential new drug candidates to treat tissue repair, fibrosis and cancer, and said that was on track for a first clinical study in early 2015.
It recently appointed a new chief executive Olav Hellebo, succeeding Michael Hunt, who headed the company from 2005 and remains chief financial officer.
Chairman Bryan Morton said: "The business benefits from a strong balance sheet and the backing of high calibre institutional investors and a management team focused on the delivery of clinical proof-of-concept data and associated value generation across its programmes over the next two year
The shares, which peaked at 9p four years ago, were unchanged at 3.38p, valuing the business at £60m.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article